Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

Aardvark Therapeutics (AARD) is facing a securities class action over alleged non-disclosure of safety issues with ARD-101, including claims that clinical/regulatory/commercial prospects were overstated. The alleged truth emerged Feb. 27, 2026, when the company voluntarily paused its Phase 3 HERO trial; Aardvark shares then fell $7.02 (-56.2%) to close at $5.47 on Mar. 2, 2026. The lead-plaintiff deadline is set for Oct. 13, 2026, which keeps legal overhang risk elevated for biotech investors.

Analysis

AARD is no longer a “lawyer headline” story; it is a probability-weighting story where the base case has shifted from a clean binary readout to a delayed, higher-variance approval path. The legal filing matters mainly because it keeps the safety issue in the tape, but the economic damage already came from the trial pause: every month of delay lowers the present value of a one-asset biotech and raises the odds of a dilutive financing before any true de-risking event.

Second-order, this is bearish for the broader early-stage obesity / appetite-modulation complex: once a mechanism picks up a cardiac safety stain, investors usually demand a much larger data package and a lower valuation multiple across adjacent names. That tends to reallocate capital toward de-risked incumbents like NVO/LLY and away from small-cap clinical-stage substitutes, even if the specific mechanism differs, because the market is effectively repricing “safety optionality” across the group.

The near-term trade is not the lawsuit itself; it is whether management can produce a credible restart plan with tighter dose boundaries and a clean cardiology narrative. If not, the next catalyst is likely cash burn, partnership abandonment, or a reverse-split/dilution cycle over 1-3 months. The contrarian point is that the stock may already have discounted much of the legal and clinical disappointment, so chasing a fresh short here is lower quality than shorting a relief rally on any restart rumor.

Key Decisions for Investors

• Do not chase an immediate short in AARD at the open; wait for a 15-25% relief bounce or a management update, then use that strength to short with a tight stop above the post-news high. Time horizon: 1-4 weeks; thesis breaks if HERO restarts with unchanged economics and no new cardiac signal.
• Relative-value: long NVO or LLY vs short XBI as a cleaner expression of safety-premium rotation away from small-cap obesity speculation. Time horizon: 1-3 months; risk/reward improves if broader biotech sentiment weakens on any additional safety headline.
• Set an alert on AARD for any trial-restart language, cash runway disclosure, or financing commentary. If the company signals >6 months of delay without a partnering framework, treat that as confirmation of dilution risk and add to the short.
• Avoid long exposure to AARD until the cardiology dataset is independently auditably clean; a lawsuit headline alone is not a durable catalyst for a squeeze. Falsifier: a credible restart with restricted dosing and no further adverse-signal follow-up from management or regulators.